دورية أكاديمية
أعرض في EDS

Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: A retrospective cohort study.

التفاصيل البيبلوغرافية
العنوان: Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: A retrospective cohort study.
المؤلفون: Hussain Alsayed HA; Pharmacy Department, Dubai Health Authority, Dubai, United Arab Emirates., Saheb Sharif-Askari F; Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates., Saheb Sharif-Askari N; Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates., Hussain AAS; Pharmacy Department, Dubai Health Authority, Dubai, United Arab Emirates., Hamid Q; Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates.; Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.; Meakins-Christie Laboratories, Research Institute of the McGill University Health Center, Montreal, Quebec, Canada., Halwani R; Sharjah Institute of Medical Research, University of Sharjah, Sharjah, United Arab Emirates.; Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.; Prince Abdullah Ben Khaled Celiac Disease Chair, Department of Pediatrics, Faculty of Medicine, King Saud University, Riyadh, Saudi Arabia.
المصدر: PloS one [PLoS One] 2021 Oct 26; Vol. 16 (10), pp. e0258643. Date of Electronic Publication: 2021 Oct 26 (Print Publication: 2021).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: Alanine*/analogs & derivatives , Alanine*/therapeutic use , Alanine*/administration & dosage , Adenosine Monophosphate*/analogs & derivatives , Adenosine Monophosphate*/therapeutic use , Adenosine Monophosphate*/administration & dosage , COVID-19 Drug Treatment* , Intensive Care Units* , Antiviral Agents*/therapeutic use , Antiviral Agents*/administration & dosage , COVID-19*/mortality , COVID-19*/epidemiology , Respiration, Artificial*, Humans ; Male ; Female ; Retrospective Studies ; Middle Aged ; Aged ; Treatment Outcome ; SARS-CoV-2/isolation & purification ; Hospitalization
مستخلص: Objectives: Remdesivir is one of the most widely recommended and used medications for COVID-19 treatment. However, different outcomes have been reported for hospitalized patients with COVID-19 treated with remdesivir. Specifically, the effect of the timing of remdesivir initiation (from patient's symptom onset) on clinical outcomes in COVID-19 patients has not been investigated.
Methods: This is a retrospective cohort study of patients hospitalized with COVID-19 and treated with or without remdisivir. The primary outcome was patient's recovery rate, defined as clinical improvement and patient's discharge by day 14 of symptom onset. The secondary outcome was the need for intensive care unit (ICU) admission, mechanical ventilation, and mortality within 28 days of patient's symptom onset.
Results: Out of 323 hospitalized adults with COVID-19, 107 (33.1%) received no remdesivir during their hospital stay, 107 (33.1%) received remdesivir early within 7 days of the symptom onset, and 109 (33.7%) received it at 8 days or later of symptom onset. At day 14 following symptom onset, higher proportion of patients recovered in the early remdesivir compared to the late remdesivir cohort, or patients who did not receive remdesivir (adjusted odds ratio, aOR, 2.65; 95% confidence interval [CI], 1.31 to 5.35). Moreover, early administration of remdesivir was associated with lower admission to intensive care unit (adjusted hazard ratio [aHR], 0.31; 95% CI, 0.15 to 0.64), less need for mechanical ventilation (aHR, 0.22; 95% CI, 0.10 to 0.51), and lower mortality at 28 days (aHR, 0.15; 95% CI, 0.04 to 0.53), as compared to the late remdesivir cohort or patients who did not receive remdesivir.
Conclusion: Early administration of remdesivir within 7 days of symptom onset is associated with less need for mechanical ventilation and lower 28-days mortality.
Competing Interests: The authors have declared that no competing interests exist.
References: Clin Infect Dis. 2020 Jul 24;:. (PMID: 32706859)
Cell Res. 2020 Mar;30(3):269-271. (PMID: 32020029)
Sci Transl Med. 2017 Jun 28;9(396):. (PMID: 28659436)
Lancet. 2020 Mar 28;395(10229):1054-1062. (PMID: 32171076)
Lancet. 2020 Feb 15;395(10223):e30-e31. (PMID: 32032529)
Lancet. 2020 May 16;395(10236):1569-1578. (PMID: 32423584)
Lancet Infect Dis. 2020 Jun;20(6):669-677. (PMID: 32240634)
Nat Commun. 2020 Jan 10;11(1):222. (PMID: 31924756)
J Clin Med. 2020 Apr 24;9(4):. (PMID: 32344679)
N Engl J Med. 2020 Nov 5;383(19):1813-1826. (PMID: 32445440)
N Engl J Med. 2021 Apr 22;384(16):1503-1516. (PMID: 33631066)
Nature. 2020 Sep;585(7824):273-276. (PMID: 32516797)
N Engl J Med. 2021 Feb 25;384(8):693-704. (PMID: 32678530)
BMJ. 2020 Jul 30;370:m2924. (PMID: 32732352)
N Engl J Med. 2021 Feb 11;384(6):497-511. (PMID: 33264556)
N Engl J Med. 2020 May 7;382(19):1787-1799. (PMID: 32187464)
JAMA. 2020 Sep 15;324(11):1048-1057. (PMID: 32821939)
Sci Transl Med. 2020 Apr 29;12(541):. (PMID: 32253226)
J Med Syst. 2020 Oct 25;44(12):202. (PMID: 33099706)
المشرفين على المادة: 3QKI37EEHE (remdesivir)
OF5P57N2ZX (Alanine)
415SHH325A (Adenosine Monophosphate)
0 (Antiviral Agents)
تواريخ الأحداث: Date Created: 20211026 Date Completed: 20240725 Latest Revision: 20240725
رمز التحديث: 20240726
مُعرف محوري في PubMed: PMC8547637
DOI: 10.1371/journal.pone.0258643
PMID: 34699552
قاعدة البيانات: MEDLINE
الوصف
تدمد:1932-6203
DOI:10.1371/journal.pone.0258643